CoChat
Sign Up
Cited by 279Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 255 of the 255 references it cites were found in a registry or an index.

Alzheimer's Disease and Type 2 Diabetes: A Critical Assessment of the Shared Pathological Traits

Open access
Chatterjee, Shreyasi, Mudher, Amritpal·2018·Frontiers in Neuroscience
DOI 10.3389/fnins.2018.00383PMC PMC6008657
Open this paper in CoChat — free accountOpen PDF

Abstract

Alzheimer's disease (AD) and Type 2 Diabetes Mellitus (T2DM) are two of the most prevalent diseases in the elderly population worldwide. A growing body of epidemiological studies suggest that people with T2DM are at a higher risk of developing AD. Likewise, AD brains are less capable of glucose uptake from the surroundings resembling a condition of brain insulin resistance. Pathologically AD is characterized by extracellular plaques of Aβ and intracellular neurofibrillary tangles of hyperphosphorylated tau. T2DM, on the other hand is a metabolic disorder characterized by hyperglycemia and insulin resistance. In this review we have discussed how Insulin resistance in T2DM directly exacerbates Aβ and tau pathologies and elucidated the pathophysiological traits of synaptic dysfunction, inflammation, and autophagic impairments that are common to both diseases and indirectly impact Aβ and tau functions in the neurons. Elucidation of the underlying pathways that connect these two diseases will be immensely valuable for designing novel drug targets for Alzheimer's disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fnins.2018.00383

Cites

255 of 255 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Overview of the diverse mechanisms by which Type 2 Diabetes can cause AD pathogenesis. Type 2 Diabetes accompanied by insulin resistance and hyperglycemia gives rise to metabolic problems in the brain and other target tissues that sets off a cascade of pathogenic processes such as oxidative stress, inflammatory responses, advanced glycation products and autophagic dysfunction. The reactive oxygen species generated by these pathways expedite the process of neuronal death. At the same time, the insulin resistance impairs the downstream signaling pathways and exacerbates the formation of Aβ oligomers and aggregates of hyperphosphorylated tau. The cumulative effect of all these factors expose the neurons to a range of assaults and gradually result in the loss of synapses and neuronal death.
Figure 1 Overview of the diverse mechanisms by which Type 2 Diabetes can cause AD pathogenesis. Type 2 Diabetes accompanied by insulin resistance and hyperglycemia gives rise to metabolic problems in the brain and other target tissues that sets off a cascade of pathogenic processes such as oxidative stress, inflammatory responses, advanced glycation products and autophagic dysfunction. The reactive oxygen species generated by these pathways expedite the process of neuronal death. At the same time, the insulin resistance impairs the downstream signaling pathways and exacerbates the formation of Aβ oligomers and aggregates of hyperphosphorylated tau. The cumulative effect of all these factors expose the neurons to a range of assaults and gradually result in the loss of synapses and neuronal death.CC BY · PubMed Central
Figure 2 Neuronal signaling mechanisms in a state of insulin sensitivity and insulin resistance. In the insulin sensitive state insulin binds to the receptor and activates the insulin receptor tyrosine kinase that initiates a cascade of phosphorylation events at the IRS/PI3K/AKT and Ras/Raf/ERK pathways. AKT phosphorylates GSK-3β at the inhibitory serine 9 residue and allows tau to maintain its physiological function of binding to microtubules and facilitates normal axonal transport of neuronal vesicles. In a state of insulin resistance, GSK-3β is activated by phosphorylation at Tyrosine 216 residue and hyperphosphorylates tau at pathological epitopes. Hyperphosphorylated tau then detaches from the microtubules and aggregates to form neurofibrillary tangles. Likewise, in the presence of excess insulin, the insulin degrading enzyme (IDE) is unable to degrade and facilitate clearance of Aβ oligomers that act as a competitive substrate for insulin. Thus, insulin resistance facilitates the formation of both Aβ and tau oligomers.
Figure 2 Neuronal signaling mechanisms in a state of insulin sensitivity and insulin resistance. In the insulin sensitive state insulin binds to the receptor and activates the insulin receptor tyrosine kinase that initiates a cascade of phosphorylation events at the IRS/PI3K/AKT and Ras/Raf/ERK pathways. AKT phosphorylates GSK-3β at the inhibitory serine 9 residue and allows tau to maintain its physiological function of binding to microtubules and facilitates normal axonal transport of neuronal vesicles. In a state of insulin resistance, GSK-3β is activated by phosphorylation at Tyrosine 216 residue and hyperphosphorylates tau at pathological epitopes. Hyperphosphorylated tau then detaches from the microtubules and aggregates to form neurofibrillary tangles. Likewise, in the presence of excess insulin, the insulin degrading enzyme (IDE) is unable to degrade and facilitate clearance of Aβ oligomers that act as a competitive substrate for insulin. Thus, insulin resistance facilitates the formation of both Aβ and tau oligomers.CC BY · PubMed Central
Figure 3 Insulin signaling also controls mTOR pathway that inhibits autophagy. Both insulin resistance in Type 2 Diabetes and Alzheimer's disease impairs the formation of autophagosomes and disrupts lysosomal function. Autophagosomes fuse with lysosomes to form autolysosomes. These autolysosomes have impaired lysosomal function in AD and T2DM and accumulate Aβ and tau aggregates. Undigested toxic aggregates are secreted out of the neurons and propagate toxic oligomers in adjacent neurons.
Figure 3 Insulin signaling also controls mTOR pathway that inhibits autophagy. Both insulin resistance in Type 2 Diabetes and Alzheimer's disease impairs the formation of autophagosomes and disrupts lysosomal function. Autophagosomes fuse with lysosomes to form autolysosomes. These autolysosomes have impaired lysosomal function in AD and T2DM and accumulate Aβ and tau aggregates. Undigested toxic aggregates are secreted out of the neurons and propagate toxic oligomers in adjacent neurons.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 255 references

Cited by

Sorted by citations

Items 201–279 of 279

Related

See all

Metadata

Authors
Chatterjee, S., & Mudher, A.
Affiliations
University of Southampton (GB)
Corresponding author
Chatterjee, Shreyasi
ORCID
Venue
Frontiers in Neuroscience
Publisher
Frontiers Media SA
Published
2018-06-08
Volume
12
Pages
383-383
ISSN
1662-453X (ISSN-L)
DOI
10.3389/fnins.2018.00383
PMC
PMC6008657
OpenAlex
W2804519474
Cited by
270
References
255
Citations by year
2026: 27 · 2025: 41 · 2024: 29 · 2023: 44 · 2022: 39 · 2021: 43 · 2020: 33 · 2019: 13 · 2018: 1
FWCI
2.95
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Neuroscience (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Nottingham Trent University's Institutional Repository (Nottingham Trent Repository) (acceptedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • ePrints Soton (University of Southampton) (submittedVersion)
Funders
University of Southampton
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
Alzheimer's disease, type 2 diabetes, insulin resistance, amyloid-beta, tau hyperphosphorylation, synaptic dysfunction, neuroinflammation, autophagy dysfunction, shared pathophysiology, therapeutic target

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review